Effect of cholestyramine on composition of duodenal bile in obese human subjects.
D000284:Administration, Oral; D000328:Adult; D000924:Anticholesteremic Agents / Q000009:adverse effects; D001647:Bile Acids and Salts / Q000032:analysis / Q000096:biosynthesis*; D001835:Body Weight; D002247:Carbon Isotopes; D002769:Cholelithiasis / Q000209:etiology; D002784:Cholesterol / Q000032:analysis / Q000097:blood / Q000378:metabolism; D002792:Cholestyramine Resin / Q000008:administration & dosage / Q000494:pharmacology*; D004035:Diet Therapy; D004386:Duodenum; D005215:Fasting; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007441:Intubation, Gastrointestinal; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000378:metabolism*; D010743:Phospholipids / Q000032:analysis; D010919:Placebos; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
D000924:Anticholesteremic Agents; D001647:Bile Acids and Salts; D002247:Carbon Isotopes; D010743:Phospholipids; D010919:Placebos; D014280:Triglycerides; D002792:Cholestyramine Resin; D002784:Cholesterol